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1. Development of the myofibroblast concept
The phenomena of wound contraction and scar retrac-
 w x.tion are known since old ages for review see 1 . In the
first part of our century, the work of Carrel and Lecomte
du Nouy has contributed to the notion that the forces¨
producing wound contraction are generated within the
w xgranulation tissue itself 2 . These forces were generally
considered to depend on extracellular matrix rearrange-
ments; however, Abercrombie and co-workers reported, in
the fifties, that fibroblasts exert tractional forces in vitro
w x3 . Similarly, Hoffmann-Beerling showed that addition of
ATP to permeabilized fibroblasts in culture produces a
w xcontraction of their cytoplasm 4 . In this context, and in
the context of emerging work on cytoskeleton morphology
w xand function 5 , the ultrastructural observation made in
our laboratory in 1971 that during granulation tissue evolu-
 .tion fibroblasts acquire smooth muscle SM cell features,
such as the presence of cytoplasmic microfilament bundles
w x6 , lead to the proposition that these cells are the source of
the force producing wound contraction, and probably con-
nective tissue retraction during fibrotic phenomena. Shortly
thereafter, it was shown that strips of granulation tissue
isolated and placed in a pharmacological bath would con-
tract and relax under the influence of substances which are
known to be capable of contracting and relaxing SM cells
w x 7,8 . It is noteworthy particularly because this observa-
.tion has never been developed that granulation tissues
from different locations respond differently to the same
agonist or antagonist stimulus, suggesting that the capacity
to react with contraction to a given stimulus by fibroblastic
w xcells depends on their location 8 . The name myofibrob-
last was suggested for this modified and possibly contrac-
w xtile fibroblast 7 .
During the next few years, several laboratories reported
by means of ultrastructural techniques the presence of
myofibroblasts in several lesions characterized by fibrosis
w x w xand retraction such as fibromatoses 9 , liver cirrhosis 10 ,
w x w xpulmonary 11 and renal 12 fibrosis. The presence of
myofibroblasts was also shown in normal tissues in loca-
tions where a certain degree of tension was needed to
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w xfunction, such as the theca externa of the ovary 13 , the
w x w xalveolar septum 14 and the intestinal pericriptal cells 15 .
Hence, the concept was developed that in both normal and
pathological situations myofibroblasts develop in response
to traction stimuli and can exert a force producing tissue
resistance and, particularly in pathological cases, tissue
 w x.deformation for review see 16 .
Because of the emerging concept that non-muscle cells
contain contractile proteins, which up to that time had been
considered typical of muscle cells, and because of the
description of other cytoskeletal structures, such as micro-
tubules and intermediate filaments, a considerable effort
was made by our as well as some other laboratories in the
characterization of contractile and cytoskeletal elements
 w x.present in myofibroblasts for review see 17 . It was
shown that myofibroblasts contain higher amounts of poly-
merized actin, as compared to normal fibroblasts in vivo
w x18 . It was also shown that normal tissues containing
myofibroblasts, such as the lung alveolus, would produce
contraction upon the stimulus of agents contracting SM
w xcells 19 . A significant advance was the production of an
w xantibody against a-SM actin 20 , one of the six actin
isoforms present in mammalian tissues and considered to
w xbe typical for vascular SM cells 21 . The use of this
antibody showed that a-SM actin is expressed temporarily
in granulation tissue of an experimental wound and disap-
w xpears when the scar develops 22 . Thus, an actin isoform
typical of SM cells is expressed during wound healing in
granulation tissue fibroblasts; this expression coincides
with the phenomenon of wound contraction. Studies by
several laboratories demonstrated the presence of a-SM
actin in myofibroblastic cells present in fibrotic tissues of
w x w xdifferent organs such as the liver 23,24 , the lung 25 , the
w x w x w xkidney 26 , the heart 27,28 and the breast 29–31 ;
moreover, a-SM actin was suggested as the most signifi-
cant marker of myofibroblastic cells, at least in pathologi-
w xcal settings 17 . The presence of myofibroblasts in my-
ocardial granulation tissue following an infarct has been
w xshown by means of ultrastructure 32 to persist for a long
time. The finding was confirmed by immunohistochem-
w xistry 33 . It is noteworthy that in old myocardial scars,
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fibroblastic cells still express a-SM actin, probably be-
w xcause of the continuous tension present in these areas 27 .
In myocardial, as well as in cutaneous granulation tissue
myofibroblasts are spatially highly organized. Recently, it
has been shown that the myocardial myofibroblasts ex-
press a homologue of drosophila tissue polarity gene,
frizzled, when they migrate into granulation tissue; this
w xmay represent the signal for alignment 28 . Another phe-
nomenon in which the modulation between fibroblast and
myofibroblast could play an important role is the fibrosis
development during heart failure. Angiotensin II has been
suggested to be important for fibrosis formation in this
w xsituation 34 .
Further work demonstrated that myofibroblasts, accord-
ing to the pathological situation, may express other mark-
ers of SM cells, such as SM myosin heavy chains and
desmin, the intermediate filament protein characteristic of
w xmuscle cells 16,17 . Other muscular proteins described in
myofibroblasts were caldesmon, SM22 and tropomyosin
w x31 . a-SM actin is the SM cell marker generally present in
myofibroblasts of normally healing granulation tissue; other
markers appear in more permanent fibrotic situations such
as liver cirrhosis and become notably expressed in the
stroma reaction to epithelial tumors, e.g. breast cancer
w x30,31,35,36 . Thus, it is possible to conclude that during
the evolution of fibrosis, fibroblasts acquire SM cell fea-
tures; these appear temporarily in normal wound healing
and more permanently in irreversible fibrotic situations.
The presence of myofibroblasts was shown to coincide
with collagen type III expression in Dupuytren’s nodules
w x37 ; this collagen isoform is known to be present in
remodeling connective tissue. In addition to these early
biochemical observations, more precise in situ hybridiza-
tion studies showed that myofibroblasts, characterized by
the expression of a-SM actin, were the cells responsible
for collagen type I mRNA production in pulmonary fibro-
w xsis 38 .
Studies aimed at the elucidation of the mechanisms
regulating the transition between granulation tissue and
scar formation demonstrated that apoptosis is the mecha-
nism through which myofibroblasts disappear during this
w xtransition 39 . This observation clarified an important
aspect of wound healing and suggested that hypertrophic
scar formation may be the consequence of a lack of
myofibroblast apoptosis at the appropriate time of healing.
The role of myofibroblasts in wound contraction was
confirmed by work showing that during fetal wound heal-
ing, when regeneration phenomena rather than scarring
predominate, there is no appearance of myofibroblasts
w x33 .
2. Agents influencing myofibroblast evolution
Another important aspect of myofibroblast research has
been the work explaining the factors which influence the
development and the disappearance of these cells. Essen-
tially, this work has concentrated on cytokines and growth
factors. The observation that g-interferon decreases the
w xexpression of a-SM actin in SM cells 40 suggested us to
verify this possibility in granulation tissue and fibrotic
tissues. Indeed, g-interferon decreases a-SM actin expres-
w xsion in cultured fibroblasts and in vivo as well 41 . The
most extensive studies on this subject have been done
w xusing the model of liver fibrosis 23,42 . Moreover, pilot
clinical studies have suggested that g-interferon applica-
tion is efficient in reducing hypertrophic scars and fibro-
w xmatosis lesions 43 .
By testing several cytokines in an experimental model
consisting of their topical application to the rat subcuta-
neous tissue through an osmotic mini pump, it was shown
that TNF, IL-1 and PDGF do not stimulate myofibroblast
formation, even when they elicit a granulation tissue re-
sponse, whereas TGF-b1 and -b2, and more surprisingly
GM-CSF, regularly stimulate the appearance of a-SM
w xactin rich myofibroblasts 44,45 . TGF-b1 and -b2 appear
to exert a very powerful a-SM actin synthesis, stimulating
w xactivity in cultured fibroblasts 46,47 . If one considers that
TGF-b is known since a long time to exert a profibrotic
activity and specifically to stimulate collagen type I syn-
w xthesis 48 , one can conclude that this cytokine is probably
the most critical for the development of scarring and
fibrosis. It is noteworthy that TGF-b can induce a-SM
actin expression in cultured fibroblastic cells in the ab-
sence of serum, that is in the absence of cell replication
w xwhich indicates a de novo synthesis of this protein 46 .
The action of GM-CSF appears to be indirect in that, when
GM-CSF is applied to fibroblastic cells in culture, no
a-SM actin synthesis is stimulated whereas a-SM actin
rich myofibroblasts are seen after local administration of
GM-CSF in the subcutaneous tissue. The same is true
when GM-CSF is applied either directly, or through a viral
w xvector to the lung alveoli 49 . Here the administration of
GM-CSF is followed by TGF-b1 expression and then by
w xa-SM actin and collagen expression 49 . Some prelimi-
nary research indicates that IL-10 could also play a role in
the stimulation of myofibroblast development in the kid-
w xney 50 . Taken together, these results suggest that local
GM-CSF application could, either directly or indirectly
through the accumulation of stimulated macrophages, elicit
an important expression of TGF-b1 which in turn would
induce a-SM actin and collagen expression, thus resulting
in fibrotic changes or scarring.
A more recent observation in our laboratory has shown
that the action of TGF-b1 is mediated through the ED-A
w xportion of cellular fibronectin 51 . This conclusion is
based on the observation that antibodies specific for the
ED-A sequence inhibit the action of TGF-b in inducing
both a-SM actin and collagen mRNA and protein expres-
sion. Thus, myofibroblast development probably depends
on both cytokine stimulation and extracellular matrix orga-
nization. It is noteworthy that TGF-b1 elicits the synthesis
w xof ED-A fibronectin in vitro 52 .
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3. Mechanisms of myofibroblast activity
Observations by several laboratories have indicated that
fibroblastic cells in vitro exert mainly isometric traction
w xforces rather than an isotonic contractile activity 53 . It is
probable that a similar mechanism takes place in vivo
during granulation tissue contraction. It has been postu-
lated that cytoskeletal elements interconnecting different
cells are organized as a tensegrity structure in which
cytoskeletal components such as microtubules or interme-
diate filaments exert a resistance to the tension produced
w xby contractile elements such as actin and myosin 54 . In
this context, an interesting aspect of myofibroblast re-
search has concerned the role of a-SM actin in the genera-
tion of myofibroblast contractile forces. In addition to
being a marker of myofibroblast differentiation, a-SM
actin could be functionally important for myofibroblast
contraction if one takes into account the fact that a-SM
actin is expressed throughout the philogenetic scale in cells
whose main function is contraction, such as vascular SM
cells or myoepithelial cells. Actin isoforms are very con-
served and exhibit relatively small differences in amino
acid sequence, which probably correspond to functional
differences. We have recently characterized the sequence
corresponding to the epitope of the monoclonal antibody
against a-SM actin which is Ac-EEED and shown that this
w xsequence is important for a-SM actin polymerization 55 .
Indeed the incubation of a-SM actin but not of other actin
isoforms with the a-SM actin specific antibody or with its
Fab fragment accelerates a-SM actin polymerization. Con-
versely, the microinjection of the epitopic peptide into
fibroblastic or SM cells inhibits selectively a-SM actin
polymerization. This observation leads one to conceive the
possibility of eliminating selectively a-SM actin from
stress fibers of a given cell and this offers a tool for testing
the role of this protein in fibroblastic cell shape mainte-
nance and contractile activity. Recent work has shown that
inhibition of a-SM actin expression in SM cells andror
fibroblasts increases their motility and likely decreases
w xtheir contractile activity 56 . Hence, it is possible that
a-SM actin plays an important role for the development of
myofibroblastic force; if this is verified by in vivo experi-
ments, one could envisage the possibility of influencing
wound contraction by treating wounds or fibrotic tissues
with the a-SM actin N-terminal peptide.
In conclusion, it appears that during the last 25 years
the concept that cell activity is the main source of force
generation within granulation tissue has gained general
acceptance. How force is produced remains to be deter-
mined, but it is increasingly accepted that the presence of
a-SM actin is instrumental for this action. Many of the
factors influencing synthesis and disappearance of a-SM
actin are presently known and it is now possible to envis-
age the study of its role in myofibroblast activity. We are
confident that during the next years more data will become
available explaining the biological activity of the myofi-
broblast and possibly allowing the modulation of its activ-
ity in order to accelerate and reduce wound contraction
and fibrosis formation.
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